SCHEMBL2989087

SCHEMBL2989087

Nc1nccc(-c2cccc(Cl)c2F)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 3/20 0.61
DYRK1A Q13627 4/20 0.56
KDM4E B2RXH2 3/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CDK5 Q00535 5/20 0.48
CDK5R1 Q15078 5/20 0.48
CCNT1 O60563 2/20 0.48
CCNA2 P20248 2/20 0.48
CDK2 P24941 2/20 0.48
CDK9 P50750 2/20 0.48
CCNA1 P78396 2/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PRKACA P17612 2/20 0.46
AURKA O14965 1/20 0.46
HSP90AA1 P07900 1/20 0.46
ADORA2A P29274 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13977724 0.84 JAK2 (0.55) KMODYRK1AKDM4ERAB9ASMN1; SMN2
SCHEMBL1914955 0.83 HSP90AA1 (0.59) KMODYRK1AKDM4ERAB9ACDK5
SCHEMBL30353577 0.76 FEN1 (0.57) DYRK1AKDM4ERAB9ASMN1; SMN2CDK5
SCHEMBL5140478 0.76 FEN1 (0.57) DYRK1AKDM4ERAB9ASMN1; SMN2CDK5
SCHEMBL4181919 0.75 JAK2 (0.80) DYRK1ACDK5CCNT1CCNA2CDK2
SCHEMBL503736 0.75 CDK5 (0.53) KMODYRK1AKDM4ERAB9ACDK5
SCHEMBL29889857 0.75 CDK5 (0.53) DYRK1AKDM4ERAB9ACDK5CDK5R1
SCHEMBL21908761 0.75 CDK5 (0.53) DYRK1AKDM4ERAB9ACDK5CDK5R1
SCHEMBL28771445 0.73 DYRK1A (0.51) KMODYRK1AKDM4ERAB9ASMN1; SMN2
SCHEMBL30775416 0.72 MAP3K14 (0.57) KMODYRK1AKDM4ERAB9ACDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150259329-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA CELLULAR THERAPIES INC (US) 2015-09-17 US disclosed
US-9056837-B2 Heterocycle compounds and uses thereof INTRA-CELLULAR THERAPIES, INC. (US) 2015-06-16 US disclosed
US-20130123269-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA-CELLULAR THERAPIES, INC. (US) 2013-05-16 US disclosed
US-8367686-B2 Heterocycle compounds and uses thereof INTRA-CELLULAR THERAPIES, INC. (US) 2013-02-05 US disclosed
US-20100173924-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA-CELLULAR THERAPIES INC. 2010-07-08 US disclosed
EP-2166858-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF Intra-Cellular Therapies, Inc. (US) 2010-03-31 EP disclosed
WO-2008153959-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA-CELLULAR THERAPIES, INC. (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259329-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF PYGB, BACE1, APP KMO 806/4885DYRK1A 2580/4885KDM4E 3588/4885
US-20100173924-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF PYGB, BACE1, APP KMO 712/4885DYRK1A 2418/4885KDM4E 3515/4885
US-20130123269-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF PYGB, BACE1, APP KMO 806/4885DYRK1A 2580/4885KDM4E 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.